CSL shares slide again in March — but is a comeback brewing?

It’s been another disappointing month for shareholders in CSL Ltd (ASX: CSL) shares.

CSL shares continued their downward trend, falling another 3.6% in March.

That extends the damage to more than 44% over the past 12 months and almost 19% so far in 2026.

So, what’s going on?

Clear reason to hit ‘sell’

The company’s latest half-year result didn’t do investors any favours. CSL reported softer performance, with underlying profit declining and revenue edging lower. Policy changes, restructuring costs, and impairments all weighed on the result. It was giving the market a clear reason to hit the sell button on CSL shares.

On the surface, that explains the weak price of CSL shares.

But dig a little deeper, and the picture looks very different.

CSL remains a global leader in plasma therapies and vaccines, supplying critical treatments for chronic and rare diseases. These aren’t optional products — patients depend on them regardless of economic conditions.

That gives CSL a powerful defensive edge. Demand is not only strong but highly recurring, providing a stable and resilient revenue base even in uncertain times.

Regaining momentum

And there are signs things are already improving.

Momentum is quietly building beneath the surface. CSL recently delivered solid earnings growth, driven by rising plasma collections and improving margins in its core CSL Behring division. Its vaccine arm, Seqirus, is also adding diversification and supporting longer-term growth.

Looking ahead, management expects both revenue and profit to continue climbing as operating conditions normalise and efficiencies improve.

In other words, the business may be regaining momentum — even if the price of CSL shares hasn’t caught up yet.

So, what could happen next?

Analysts are backing a recovery. Broker sentiment on CSL shares remains broadly positive, with most maintaining buy or outperform ratings. The average 12-month price target sits around $214.00, suggesting potential upside of roughly 52% from current levels.

UBS is firmly in the bullish camp on CSL shares. The broker has a buy rating and a $235 price target, implying a possible 67% upside over the next year. Some forecasts are even more bullish, tipping gains of up to 96%.

Margin pressure, currency impacts

Of course, there are still risks. CSL has faced ongoing headwinds, including margin pressure, integration challenges, and currency impacts. If earnings recovery takes longer than expected, the share price could remain under pressure.

There’s also the broader issue of market sentiment. Even high-quality healthcare stocks can fall out of favour, especially when investors rotate into other sectors.

The bottom line? CSL shares have had a rough run, but the underlying business tells a much more resilient story. If momentum continues to build, this healthcare giant could be quietly setting up for a comeback.

The post CSL shares slide again in March — but is a comeback brewing? appeared first on The Motley Fool Australia.

More reading

• If I could buy only 1 ASX 200 share right now, it would be…
• How are these 5 ASX share giants really tracking in 2026?
• Is it time to get greedy with CSL shares?
• Why I’d buy dirt-cheap ASX shares now and aim to hold them for a decade
• Is it too late to start investing in ASX shares in your 40s?

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.